0	0	1999-09-23	CD	O	O	B-Num
0	1	16	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	01	CD	O	B-NP	I-Num
0	4	MAKER	NNP	O	I-NP	O
0	5	OF	IN	O	B-PP	O
0	6	DRUG	NN	O	B-NP	O
0	7	TESTS	NNS	O	I-NP	O
0	8	FACES	VBZ	O	B-VP	O
0	9	QUESTIONS	NNP	O	B-NP	O
0	10	FROM	IN	O	O	O
0	11	SHAREHOLDERS	NNP	O	O	O

1	0	KINDERHOOK	NNP	O	B-NP	B-Loc
1	1	COMMA	COMMA	O	O	O
1	2	N.Y.	NNP	O	B-NP	B-LocStat
1	3	_	NN	O	I-NP	O
1	4	When	WRB	O	O	O
1	5	a	DT	O	B-NP	O
1	6	company	NN	O	I-NP	B-OrgCorp
1	7	's	POS	O	B-NP	O
1	8	stock	NN	O	I-NP	O
1	9	price	NN	O	I-NP	O
1	10	has	VBZ	O	B-VP	O
1	11	taken	VBN	O	I-VP	O
1	12	a	DT	O	B-NP	O
1	13	beating	VBG	O	I-NP	O
1	14	and	CC	O	O	O
1	15	legal	JJ	O	B-NP	O
1	16	costs	NNS	O	I-NP	O
1	17	are	VBP	O	B-VP	O
1	18	eating	VBG	O	I-VP	O
1	19	up	IN	O	O	O
1	20	profits	NNS	O	B-NP	O
1	21	despite	IN	O	B-PP	O
1	22	record	NN	O	B-NP	O
1	23	sales	NNS	O	I-NP	O
1	24	COMMA	COMMA	O	O	O
1	25	stockholders	NNS	O	B-NP	O
1	26	are	VBP	O	B-VP	O
1	27	apt	JJ	O	O	O
1	28	to	TO	O	B-VP	O
1	29	ask	VB	O	I-VP	O
1	30	questions	NNS	O	B-NP	O
1	31	.	.	O	O	O

2	0	That	DT	O	B-NP	O
2	1	's	VBZ	O	B-VP	O
2	2	exactly	RB	O	B-NP	O
2	3	what	WP	O	I-NP	O
2	4	about	IN	O	I-NP	O
2	5	70	CD	O	I-NP	B-Num
2	6	shareholders	NNS	O	I-NP	O
2	7	of	IN	O	B-PP	O
2	8	American	NNP	O	B-NP	B-OrgCorp
2	9	Bio	NNP	O	I-NP	I-OrgCorp
2	10	Medica	NNP	O	I-NP	I-OrgCorp
2	11	Corp.	NNP	O	I-NP	I-OrgCorp
2	12	did	VBD	O	B-VP	O
2	13	Wednesday	NNP	O	B-NP	B-Date
2	14	at	IN	O	B-PP	O
2	15	their	PP$	O	B-NP	O
2	16	annual	JJ	O	I-NP	O
2	17	meeting	NN	O	I-NP	O
2	18	at	IN	O	B-PP	O
2	19	the	DT	O	B-NP	O
2	20	company	NN	O	I-NP	B-OrgCorp
2	21	's	POS	O	B-NP	O
2	22	new	JJ	O	I-NP	O
2	23	headquarters	NN	O	I-NP	O
2	24	COMMA	COMMA	O	O	O
2	25	a	DT	O	B-NP	O
2	26	30COMMA000-square-foot	JJ	O	I-NP	B-Num
2	27	building	NN	O	I-NP	O
2	28	in	IN	O	B-PP	O
2	29	the	DT	O	B-NP	O
2	30	middle	NN	O	I-NP	O
2	31	of	IN	O	B-PP	O
2	32	a	DT	O	B-NP	O
2	33	cornfield	NN	O	I-NP	O
2	34	in	IN	O	B-PP	O
2	35	Columbia	NNP	O	B-NP	B-LocCit
2	36	County	NNP	O	I-NP	I-LocCit
2	37	.	.	O	O	O

3	0	The	DT	O	B-NP	O
3	1	company	NN	O	I-NP	B-OrgCorp
3	2	makes	VBZ	O	B-VP	O
3	3	easy-to-use	JJ	O	B-NP	O
3	4	kits	NNS	O	I-NP	O
3	5	that	IN	O	B-NP	O
3	6	test	VBP	O	B-VP	O
3	7	urine	NN	O	B-NP	O
3	8	for	IN	O	B-PP	O
3	9	the	DT	O	B-NP	O
3	10	presence	NN	O	I-NP	O
3	11	of	IN	O	B-PP	O
3	12	as	RB	O	B-NP	O
3	13	many	JJ	O	I-NP	O
3	14	as	IN	O	O	O
3	15	nine	CD	O	B-NP	B-Num
3	16	substances	NNS	O	I-NP	O
3	17	COMMA	COMMA	O	O	O
3	18	and	CC	O	O	O
3	19	can	MD	O	B-VP	O
3	20	offer	VB	O	I-VP	O
3	21	immediate	JJ	O	B-NP	O
3	22	results	NNS	O	I-NP	O
3	23	.	.	O	O	O

4	0	The	DT	O	B-NP	O
4	1	products	NNS	O	I-NP	O
4	2	COMMA	COMMA	O	O	O
4	3	marketed	VBN	O	B-VP	O
4	4	under	IN	O	B-PP	O
4	5	the	DT	O	B-NP	O
4	6	name	NN	O	I-NP	O
4	7	Rapid	NNP	O	I-NP	O
4	8	Drug	NNP	O	I-NP	O
4	9	Screen	NNP	O	I-NP	O
4	10	COMMA	COMMA	O	O	O
4	11	are	VBP	O	B-VP	O
4	12	in	IN	O	B-PP	O
4	13	great	JJ	O	B-NP	O
4	14	demand	NN	O	I-NP	O
4	15	among	IN	O	B-PP	O
4	16	clients	NNS	O	B-NP	O
4	17	like	IN	O	B-PP	O
4	18	hospitals	NNS	O	B-NP	O
4	19	and	CC	O	I-NP	O
4	20	employers	NNS	O	I-NP	O
4	21	who	WP	O	B-NP	O
4	22	screen	NN	O	B-NP	O
4	23	job	NN	O	I-NP	O
4	24	applicants	NNS	O	I-NP	O
4	25	for	IN	O	B-PP	O
4	26	drug	NN	O	B-NP	B-Medical
4	27	use	NN	O	I-NP	O
4	28	.	.	O	O	O

5	0	The	DT	O	B-NP	O
5	1	market	NN	O	I-NP	O
5	2	for	IN	O	B-PP	O
5	3	the	DT	O	B-NP	O
5	4	Rapid	NNP	O	I-NP	B-Org
5	5	Drug	NNP	O	I-NP	I-Org
5	6	Screen	NNP	O	I-NP	I-Org
5	7	has	VBZ	O	B-VP	O
5	8	grown	VBN	O	I-VP	O
5	9	so	RB	O	B-NP	O
5	10	much	RB	O	I-NP	O
5	11	that	IN	O	O	O
5	12	American	NNP	O	B-NP	B-OrgCorp
5	13	Bio	NNP	O	I-NP	I-OrgCorp
5	14	Medica	NNP	O	I-NP	I-OrgCorp
5	15	sales	NNS	O	I-NP	O
5	16	grew	VBD	O	B-VP	O
5	17	to	TO	O	B-PP	O
5	18	$7	NN	O	B-NP	B-Money
5	19	million	CD	O	I-NP	B-Num
5	20	in	IN	O	B-PP	O
5	21	its	PP$	O	B-NP	O
5	22	last	JJ	O	I-NP	O
5	23	fiscal	JJ	O	I-NP	O
5	24	year	NN	O	I-NP	O
5	25	COMMA	COMMA	O	O	O
5	26	up	IN	O	O	O
5	27	from	IN	O	B-PP	O
5	28	$2	NN	O	B-NP	B-Money
5	29	million	CD	O	I-NP	B-Num
5	30	the	DT	O	B-NP	O
5	31	year	NN	O	I-NP	O
5	32	before	IN	O	O	O
5	33	.	.	O	O	O

6	0	With	IN	O	B-PP	O
6	1	a	DT	O	B-NP	O
6	2	national	JJ	O	I-NP	O
6	3	distribution	NN	O	I-NP	O
6	4	agreement	NN	O	I-NP	O
6	5	with	IN	O	B-PP	O
6	6	Abbott	NNP	O	B-NP	B-OrgCorp
6	7	Laboratories	NNP	O	I-NP	I-OrgCorp
6	8	well	RB	O	O	O
6	9	under	IN	O	B-PP	O
6	10	way	NN	O	B-NP	O
6	11	and	CC	O	I-NP	O
6	12	clearance	NN	O	I-NP	O
6	13	from	IN	O	B-PP	O
6	14	the	DT	O	B-NP	O
6	15	U.S.	NNP	O	I-NP	B-LocCoun
6	16	Food	NNP	O	I-NP	B-Food
6	17	and	CC	O	I-NP	O
6	18	Drug	NNP	O	I-NP	O
6	19	Administration	NNP	O	I-NP	O
6	20	on	IN	O	B-PP	O
6	21	a	DT	O	B-NP	O
6	22	new	JJ	O	I-NP	O
6	23	9-drug	JJ	O	I-NP	B-Num
6	24	product	NN	O	I-NP	O
6	25	COMMA	COMMA	O	O	O
6	26	company	NN	O	B-NP	B-OrgCorp
6	27	Vice	NNP	O	I-NP	B-Peop
6	28	President	NNP	O	I-NP	I-Peop
6	29	of	IN	O	B-PP	O
6	30	Sales	NNP	O	B-NP	O
6	31	Jay	NNP	O	I-NP	B-Peop
6	32	Bendis	NNP	O	I-NP	I-Peop
6	33	predicted	VBD	O	B-VP	O
6	34	sales	NNS	O	B-NP	O
6	35	would	MD	O	B-VP	O
6	36	reach	VB	O	I-VP	O
6	37	$13	NN	O	B-NP	B-Money
6	38	million	CD	O	I-NP	B-Num
6	39	this	DT	O	B-NP	O
6	40	year	NN	O	I-NP	O
6	41	.	.	O	O	O

7	0	Still	RB	O	O	O
7	1	COMMA	COMMA	O	O	O
7	2	the	DT	O	B-NP	O
7	3	company	NN	O	I-NP	B-OrgCorp
7	4	lost	VBD	O	B-VP	O
7	5	$1.7	NN	O	B-NP	B-Money
7	6	million	CD	O	I-NP	B-Num
7	7	during	IN	O	B-PP	O
7	8	its	PP$	O	B-NP	O
7	9	last	JJ	O	I-NP	O
7	10	fiscal	JJ	O	I-NP	O
7	11	year	NN	O	I-NP	O
7	12	.	.	O	O	O

8	0	Key	NNP	O	O	B-Peop
8	1	among	IN	O	B-PP	O
8	2	its	PP$	O	B-NP	O
8	3	problems	NNS	O	I-NP	O
8	4	have	VBP	O	B-VP	O
8	5	been	VBN	O	I-VP	O
8	6	high	JJ	O	B-NP	O
8	7	manufacturing	NN	O	I-NP	O
8	8	costs	NNS	O	I-NP	O
8	9	and	CC	O	O	O
8	10	legal	JJ	O	B-NP	O
8	11	fees	NNS	O	I-NP	O
8	12	.	.	O	O	O

9	0	Company	NN	O	B-NP	B-OrgCorp
9	1	officials	NNS	O	I-NP	O
9	2	attempted	VBD	O	B-VP	O
9	3	to	TO	O	I-VP	O
9	4	reassure	VB	O	I-VP	O
9	5	the	DT	O	B-NP	O
9	6	shareholders	NNS	O	I-NP	O
9	7	.	.	O	O	O

10	0	``	``	O	O	O
10	1	Profit	NN	O	B-NP	O
10	2	eluded	VBD	O	B-VP	O
10	3	us	PRP	O	B-NP	O
10	4	mostly	RB	O	O	O
10	5	due	JJ	O	O	O
10	6	to	TO	O	B-PP	O
10	7	gross	JJ	O	O	O
10	8	-LBR-	-LBR-	O	O	O
10	9	operating	VBG	O	O	O
10	10	-RBR-	-RBR-	O	O	O
10	11	margins	NNS	O	O	O
10	12	and	CC	O	O	O
10	13	legal	JJ	O	B-NP	O
10	14	feesCOMMA	NN	O	I-NP	O
10	15	''	''	O	O	O
10	16	said	VBD	O	B-VP	O
10	17	company	NN	O	B-NP	B-OrgCorp
10	18	President	NNP	O	I-NP	B-ProfTitle
10	19	Stan	NNP	O	I-NP	B-Peop
10	20	Cipkowski	NNP	O	I-NP	I-Peop
10	21	.	.	O	O	O

11	0	``	``	O	O	O
11	1	We	PRP	O	B-NP	O
11	2	hope	VBP	O	B-VP	O
11	3	that	IN	O	O	O
11	4	both	DT	O	B-NP	O
11	5	of	IN	O	B-PP	O
11	6	those	DT	O	B-NP	O
11	7	issues	NNS	O	I-NP	O
11	8	will	MD	O	B-VP	O
11	9	be	VB	O	I-VP	O
11	10	settled	VBN	O	I-VP	O
11	11	going	VBG	O	I-VP	O
11	12	forward	RB	O	O	O
11	13	.	.	O	O	O
11	14	''	''	O	O	O

12	0	American	NNP	O	B-NP	B-LangRace
12	1	Bio	NNP	O	I-NP	O
12	2	Medica	NNP	O	I-NP	B-OrgCorp
12	3	officials	NNS	O	I-NP	O
12	4	said	VBD	O	B-VP	O
12	5	they	PRP	O	B-NP	O
12	6	plan	VBP	O	B-VP	O
12	7	to	TO	O	I-VP	O
12	8	begin	VB	O	I-VP	O
12	9	making	VBG	O	I-VP	O
12	10	in-house	JJ	O	O	O
12	11	some	DT	O	B-NP	O
12	12	components	NNS	O	I-NP	O
12	13	of	IN	O	B-PP	O
12	14	the	DT	O	B-NP	O
12	15	drug-test	JJ	O	I-NP	O
12	16	kits	NNS	O	I-NP	O
12	17	that	WDT	O	B-NP	O
12	18	are	VBP	O	B-VP	O
12	19	now	RB	O	I-VP	O
12	20	contracted	VBD	O	I-VP	O
12	21	out	IN	O	B-PP	O
12	22	to	TO	O	B-PP	O
12	23	other	JJ	O	B-NP	O
12	24	companies	NNS	O	I-NP	B-OrgCorp
12	25	.	.	O	O	O

13	0	The	DT	O	B-NP	O
13	1	company	NN	O	I-NP	B-OrgCorp
13	2	faces	VBZ	O	B-VP	O
13	3	a	DT	O	B-NP	O
13	4	lingering	VBG	O	I-NP	O
13	5	legal	JJ	O	I-NP	O
13	6	issue	NN	O	I-NP	O
13	7	COMMA	COMMA	O	O	O
13	8	a	DT	O	B-NP	O
13	9	patent	NN	O	I-NP	O
13	10	infringement	NN	O	I-NP	O
13	11	suit	NN	O	I-NP	O
13	12	that	IN	O	O	O
13	13	American	NNP	O	B-NP	B-OrgCorp
13	14	Bio	NNP	O	I-NP	I-OrgCorp
13	15	Medica	NNP	O	I-NP	I-OrgCorp
13	16	is	VBZ	O	B-VP	O
13	17	fighting	VBG	O	I-VP	B-Sport
13	18	against	IN	O	B-PP	O
13	19	four	CD	O	B-NP	B-Num
13	20	other	JJ	O	I-NP	O
13	21	companies	NNS	O	I-NP	B-OrgCorp
13	22	it	PRP	O	B-NP	O
13	23	says	VBZ	O	B-VP	O
13	24	have	VB	O	O	O
13	25	copied	VBN	O	O	O
13	26	its	PP$	O	B-NP	O
13	27	technology	NN	O	I-NP	O
13	28	and	CC	O	I-NP	O
13	29	designs	NNS	O	I-NP	O
13	30	.	.	O	O	O

14	0	Cipkowski	NNP	O	B-NP	B-Peop
14	1	said	VBD	O	B-VP	O
14	2	he	PRP	O	B-NP	O
14	3	didn	NN	O	B-NP	O
14	4	't	NN	O	I-NP	O
14	5	expect	VBP	O	B-VP	O
14	6	those	DT	O	B-NP	O
14	7	kinds	NNS	O	I-NP	O
14	8	of	IN	O	B-PP	O
14	9	battles	NNS	O	B-NP	O
14	10	to	TO	O	B-VP	O
14	11	ever	RB	O	I-VP	O
14	12	go	VB	O	I-VP	O
14	13	away	RB	O	O	O
14	14	COMMA	COMMA	O	O	O
14	15	as	IN	O	O	O
14	16	the	DT	O	B-NP	O
14	17	company	NN	O	I-NP	B-OrgCorp
14	18	will	NN	O	O	O
14	19	need	VB	O	B-VP	O
14	20	to	TO	O	I-VP	O
14	21	defend	VB	O	I-VP	O
14	22	itself	PRP	O	B-NP	O
14	23	against	IN	O	B-PP	O
14	24	patent	NN	O	B-NP	O
14	25	theft	NN	O	I-NP	O
14	26	as	IN	O	O	O
14	27	it	PRP	O	B-NP	O
14	28	continually	RB	O	O	O
14	29	improves	VBZ	O	B-VP	O
14	30	its	PP$	O	B-NP	O
14	31	products	NNS	O	I-NP	O
14	32	.	.	O	O	O

15	0	Also	RB	O	O	O
15	1	of	IN	O	B-PP	O
15	2	concern	NN	O	B-NP	O
15	3	to	TO	O	B-PP	O
15	4	shareholders	NNS	O	B-NP	O
15	5	was	VBD	O	B-VP	O
15	6	a	DT	O	B-NP	O
15	7	recent	JJ	O	I-NP	O
15	8	warning	NN	O	I-NP	O
15	9	letter	NN	O	I-NP	O
15	10	American	NNP	O	I-NP	B-OrgCorp
15	11	Bio	NNP	O	I-NP	I-OrgCorp
15	12	Medica	NNP	O	I-NP	I-OrgCorp
15	13	received	VBD	O	B-VP	O
15	14	from	IN	O	B-PP	O
15	15	the	DT	O	B-NP	O
15	16	FDA	NNP	O	I-NP	O
15	17	.	.	O	O	O

16	0	The	DT	O	B-NP	O
16	1	FDA	NNP	O	I-NP	B-Peop
16	2	said	VBD	O	B-VP	O
16	3	American	NNP	O	B-NP	B-LangRace
16	4	Bio	NNP	O	I-NP	O
16	5	Medica	NNP	O	I-NP	B-OrgCorp
16	6	didn	NN	O	I-NP	O
16	7	't	NN	O	I-NP	O
16	8	notify	VBP	O	B-VP	O
16	9	the	DT	O	B-NP	O
16	10	federal	JJ	O	I-NP	O
16	11	agency	NN	O	I-NP	B-OrgCorp
16	12	COMMA	COMMA	O	O	O
16	13	as	IN	O	O	O
16	14	required	VBN	O	B-VP	O
16	15	COMMA	COMMA	O	O	O
16	16	about	IN	O	O	O
16	17	a	DT	O	B-NP	O
16	18	significant	JJ	O	I-NP	O
16	19	change	NN	O	I-NP	O
16	20	in	IN	O	B-PP	O
16	21	the	DT	O	B-NP	O
16	22	way	NN	O	I-NP	O
16	23	results	NNS	O	B-NP	O
16	24	are	VBP	O	B-VP	O
16	25	calculated	VBN	O	I-VP	O
16	26	in	IN	O	B-PP	O
16	27	one	CD	O	B-NP	B-Num
16	28	of	IN	O	B-PP	O
16	29	its	PP$	O	B-NP	O
16	30	products	NNS	O	I-NP	O
16	31	.	.	O	O	O

17	0	Douglas	NNP	O	B-NP	B-Peop
17	1	Casterlin	NNP	O	I-NP	I-Peop
17	2	COMMA	COMMA	O	O	O
17	3	American	NNP	O	B-NP	B-OrgCorp
17	4	Bio	NNP	O	I-NP	I-OrgCorp
17	5	Medica	NNP	O	I-NP	I-OrgCorp
17	6	vice	NN	O	I-NP	B-ProfTitle
17	7	president	NN	O	I-NP	I-ProfTitle
17	8	of	IN	O	B-PP	O
17	9	operations	NNS	O	B-NP	O
17	10	COMMA	COMMA	O	O	O
17	11	said	VBD	O	B-VP	O
17	12	the	DT	O	B-NP	O
17	13	company	NN	O	I-NP	B-OrgCorp
17	14	wrote	VBD	O	B-VP	O
17	15	to	TO	O	B-PP	O
17	16	the	DT	O	B-NP	O
17	17	FDA	NNP	O	I-NP	B-Org
17	18	on	IN	O	B-PP	O
17	19	Sept.	NNP	O	B-NP	B-Date
17	20	15	CD	O	I-NP	I-Date
17	21	defending	VBG	O	O	O
17	22	its	PP$	O	B-NP	O
17	23	actions	NNS	O	I-NP	O
17	24	COMMA	COMMA	O	O	O
17	25	and	CC	O	O	O
17	26	that	IN	O	O	O
17	27	the	DT	O	B-NP	O
17	28	agency	NN	O	I-NP	B-OrgCorp
17	29	has	VBZ	O	B-VP	O
17	30	until	IN	O	B-PP	O
17	31	Sept.	NNP	O	B-NP	B-Date
17	32	30	CD	O	I-NP	I-Date
17	33	to	TO	O	B-VP	O
17	34	respond	VB	O	I-VP	O
17	35	.	.	O	O	O
